

2019–20

ANNUAL REPORT



**Consumer Healthcare
Products Australia**

Advancing consumer health through responsible self-care

CHP Australia Purpose, Vision and Mission

Our members are manufacturers and distributors of consumer healthcare products, which includes nonprescription medicines. CHP Australia also represents businesses that support the industry. These include advertising agencies and PR firms as well as legal, statistical and regulatory consultancy companies and individuals.

PURPOSE

Promote and develop the Australian consumer healthcare products industry and to help members thrive.

MISSION

To enhance the health and well-being of Australians through access to proven healthcare products.

VISION

Consumers have the information and products to practise Self-Care with confidence.

CHP AUSTRALIA STRATEGIC GOALS 2018–2021

VOICE

Relevant and influential voice in Canberra and broadly



REBRAND

As a consumer healthcare products industry association



MANUFACTURERS

Have the representation and services they need



REPUTATION

Of member companies and our industry is protected



COLLABORATION

Extend influence and effectiveness through collaboration



Contents

Chairperson and CEO's Message	2
A New Service from CHP Australia!	3
VOICE OF INDUSTRY	4
Setting the Industry Agenda during COVID-19	4
Leading on Issues Management	6
REGULATORY ENVIRONMENT	8
Driving Regulatory Reform	8
PROMOTING GREATER SELF-CARE	10
Developing a National Self-Care Policy	10
The CHP Australia Board	12
CHP Australia Members	13
Subcommittees and Working Groups	14
CHP Australia – Your Support Team	15
CHP Australia Events	16
Contact Details	18

Chairperson and CEO's Message

We reflect on a year of many opportunities and multiple unforeseen challenges, most of which resulted in significant achievements or improvements.



Lindsay Forrest



Deon Schoombie

There were again several wins in the regulatory area which will be covered in detail later in this report. We would like to single out one. Having successfully pursued a fundamental overhaul of the scheduling (switch) framework over the past 5 years, the one remaining challenge to address was data protection for S4 to S3 rescheduling. A breakthrough solution presented with the introduction of Appendix M in the Scheduling Policy Framework. This mechanism makes provision for mandating at the request of the switch applicant a post-market surveillance program for a specified period of time – a regulatory mechanism that would achieve an impact comparable to data protection.

Arguably our biggest effort during the past year was the introduction of a self-regulatory (voluntary) advertising advisory service, AdCheck, to replace the mandatory advertising pre-approvals scheme which has been in place for decades. The service was launched during a joint CHP Australia/TGA webinar; it was a huge success and attended by 500 delegates from all stakeholder groups with an interest in advertising. The original 1 July commencement date of the service was brought forward because of the high level of interest.

The adoption of self-care in national health policy remains a priority strategic goal for CHP Australia. Work on the development of a self-care policy blueprint by the Victoria University/Mitchell Institute and supported by the Australian Self Care Alliance is well advanced and the launch is scheduled for early October 2020. This will establish Australia as a world leader in the self-care policy arena.

We hosted several successful events over the past year. The highlight was the Parliamentary Function and Stakeholder Summit in November 2019 in Canberra. The event was well attended and well received and it was encouraging that so many Members of Parliament and their staff, the TGA leadership and non-parliamentary stakeholders took the time to join us. We would like to thank members who generously contributed products to our CHP Australia self-care packs, which were distributed to 100 external stakeholders.

The pandemic presented our industry, like so many others, with many novel challenges (and opportunities) that will undoubtedly continue for some time to come. To assist members during these unprecedented times a range of new services were introduced. Since February members have been receiving regular collated COVID-19 updates that included relevant news coverage, government announcements, and business and health resources. Regular member surveys were conducted to gather and share information to learn from each other regarding company responses to issues such as working remotely, return to work protocols, field force deployment and supply chain challenges.

CHP Australia has been represented on various government-led multi-stakeholder working groups and roundtables. The primary goal of these was to establish a direct conduit between industry and government, to ensure rapid flow of information gathered from industry to assist government in responding to emerging issues in a timely fashion. These included the TGA Medicines Shortages Working Group, the Department of Industry Supply Chain Roundtable and the Department of Industry Hand Sanitiser Roundtable and its four working groups.

We would like express our gratitude to the membership for their loyal support over the past year, and in particular for remaining fully engaged in committee activities – these are the lifeline of the organisation and are vital to ensure that we effectively represent the interests of the members and the industry. We also thank the CHP Australia board and the secretariat team for their commitment and guidance.

Lindsay Forrest
Chairperson

Deon Schoombie
Chief Executive Officer

A New Service from CHP Australia!

In April 2020, we announced the launch of AdCheck – an expert TGAC compliance advisory service – to commence 1 July, once the TGA mandatory pre-approvals of consumer advertising for therapeutic goods came to an end.



Mandatory pre-approvals have helped protect both advertisers and consumers from noncompliant advertising through independent, expert compliance checks. After their abolishment at 1 July 2020, companies that create and/or place ads still have the same legal responsibility to ensure their ads are compliant, but without the benefit of this compliance safety net.

With the TGA's increased sanctions and penalties for noncompliant advertising, it is now more important than ever to ensure that all direct to consumer advertisements – including social media content – complies with the Therapeutic Goods Advertising Code. If advertisers, publishers, broadcasters and media agencies do not manage their compliance obligations they risk not only heavy fines and sanctions, but also brand and reputational damage.

Based on feedback from CHP members and broader stakeholders, we developed and launched the service early, beginning 9 June for CHP members, followed by the industry-wide launch on 1 July.

AdCheck is a voluntary service providing independent, expert compliance checks and guidance on all forms of direct to consumer therapeutic goods advertising, helping to minimise the risks of noncompliance.



HIGHLIGHTS OF THE ADCHECK SERVICE INCLUDE:

Experience – At CHP Australia we have over 25 years of experience performing detailed advertising compliance checks and are well known as the benchmark regulatory experts in Australia for therapeutic goods. Our AdCheck team has in-depth expertise on the intricacies of the Therapeutic Goods Act, Regulations and Advertising Code, which is arguably the most detailed, complex legislation for consumer goods. We stay up to date on any changes and as the industry body representing therapeutic goods we have strong relationships with the TGA and the Department of Health.

Support managing complaints – As a client of CHP Australia, if a complaint arises, we will professionally assist you as indicated in our Term & Conditions. Our expertise includes many years of dealing with complaints (CRP and CHP Australia complaints processes).

Coaching and compliance training – Our aim is to assist you to reach compliance on any given ad. We provide coaching and advice on how to reach compliance for an ad; we don't just provide a 'it needs fixing' response.

Unique AdCheck verification number – CHP Australia is well known and respected throughout industry for its expertise in compliance for therapeutic goods; a CHP Australia AdCheck number assigned to compliant ads represents quality and assurance and can be verified upon request.


More information can be found on our website: adcheck.com.au

Setting the Industry Agenda during COVID-19

THE ROLE OF SELF-CARE

In this tumultuous year of COVID-19, self-care has been more critically important to the maintenance of good health than ever before. CHP Australia advocates for self-care to be elevated in national health policy. Self-care entails individuals taking greater personal interest in, and responsibility for, their health and well-being through practices including lifestyle, responsible use of medicines, diet and exercise. Increased consumer empowerment and access to medicines are key to greater self-care as shown in the Self-Care Pyramid (Figure 1).

FIGURE 1
OUR ROLE IN SELF-CARE



© CHP Australia (Consumer Healthcare Products Australia)

ADVOCATING FOR INCREASED CONSUMER ACCESS AND BALANCED REGULATION

CHP Australia continued its advocacy in 2019/2020 for greater consumer access to nonprescription medicines and for proportionate, risk-based, regulation.

Beyond the 'normal' representations to government, the TGA and other stakeholders, CHP Australia represented members on key COVID-19 related working groups and committees including the TGA Medicines Shortages Working Group, the Department of Industry Supply Chain Roundtable and the Department of Industry Hand Sanitiser Roundtable and its four working groups.

In terms of access we have seen continued substantial progress in relation to:

- The Scheduling Policy Framework
- Switch
- S3 Advertising
- Appendix M
- The potential role for sponsor-specific Risk Management Plans (RMPs) to be included within Appendix M, as a mechanism for providing incentives for switch

Our key achievements in relation to the adoption of proportionate and risk-based reforms are described in the "Driving Regulatory Reform" section.

This year, our focus on manufacturers saw a renewed interest in sustainability issues. Our key activities included:

- CHP membership of the Australian Packaging Covenant Organisation
- The establishment of our Sustainability Working Group
- VIC waste association presentation and tours (October 2019)
- Collaborations throughout the year with other industry associations
- Development of international information resources
- A submission to the NSW Department of Planning, Industry and Environment (DPIE) consultation on Plastics Plan and 20-year waste strategy
- Meetings with NSW DPIE to further develop our relationship and to represent members in the waste strategy
- Participation in NSW and VIC waste industry training events



Leading on Issues Management

As the voice of the nonprescription medicines industry with external stakeholders and in the media, CHP Australia advocates for issues important to the industry, promotes the economic and social value of the industry, protects the sector's reputation and supports consumer education about the responsible use of nonprescription medicines and self-care.

COVID-19 has presented our industry with many new challenges and placed unprecedented pressure on our members and their staff. To support members as they navigated this environment CHP Australia has:

- expanded our advocacy efforts, represented industry in additional forums, worked with new stakeholders and ensured members' issues were heard
- provided daily COVID-19 updates to help keep members informed about issues relevant to the industry during this unique period of rapid change.

Despite the challenges and changing priorities of the pandemic, CHP Australia continues to expand and deepen its engagement with political and industry stakeholders in a meaningful and impactful way, most notably:

- Securing two seats on the National Medicines Policy Review
- Securing two seats on the Industry Department's COVID-19 Supply Chain Roundtable and Hand Sanitiser Roundtable
- Broadening our touchpoints in the new Federal Parliament, including proactive engagement with the Crossbench
- Contributing to Parliamentary inquiries – Standing Committee on Health, Aged Care and Sport's Inquiry into allergies and anaphylaxis
- Engaging the Qld Government on their OTC contraceptive pill trial
- Engaging the NSW Government on their Plastics Plan and waste strategy
- Committing to work with the Pharmacy Guild of Australia and Pharmaceutical Society of Australia in our advocacy for a Common Ailments Scheme, as outlined by a UTS evaluation.

As part of our annual Canberra Stakeholders Summit, CHP Australia also hosted its first parliamentary event – a celebration of health literacy with our partner Life Education. Thanks to the generosity of our members, we distributed 100 self-care product packs to external stakeholders along with a brochure that outlined the growing contribution of our industry to the Australian economy.

We also remain at the forefront of media engagement and emerging issues management, providing media surveillance and analysis on key industry, product and ingredients issues across the Australian and International media.

CHP Australia continues to promote global and local research, including research that demonstrates the economic impact of greater consumer access to medicines and the benefits of increased focus on preventive health and self-care.



Driving Regulatory Reform

CHP Australia continues to influence outcomes at a time of unprecedented regulatory reform. Our work with members, the TGA and other stakeholders drives outcomes that are practical, proportionate, effective and implemented within realistic timeframes.

In the 12 months since July 2019, we considered 53 regulatory consultations and made submissions in relation to 37. Through our Teams, Working Groups and Subcommittees we discussed reforms and issues with members and agreed on industry positions. Through hundreds of interactions with individual members we explored regulatory complexities and provided support and advice to members.

This close collaboration between the Secretariat, the Members and other stakeholders is what drives our advocacy.

MMDR Review

CHP Australia is continuing to work with the TGA, members and other stakeholders to support and refine the ongoing roll-out of the regulatory reforms resulting from the Medicines and Medical Devices Regulation (MMDR) Review.

Advertising

Therapeutic Goods Advertising continues to be a major concern for members. Throughout the reforms, our advocacy has involved participation in the TGA consultations (public and targeted), advice to members, member workshops, meetings with the TGA and meetings with other stakeholders. In particular, our membership of the Therapeutic Goods Advertising Consultative Committee (TGACC) has allowed us to influence discussions and to obtain valuable insights for our members. Key achievements from the past 12 months include:

- Participation and presentations to the TGACC
- Improvements to the TGA's "natural" guidance
- Improvements to the TGAC (e.g. mandatory statements)
- Assisting members navigate the new TGAC, the new advertising guidelines, the new complaints processes and the new sanctions regime
- Assumption of the CHC pre-approvals delegation in November 2019
- AdCheck development and launch in July 2020
- Ongoing refinement of the AdCheck service
- Feedback to independent advertising reviews of TGA reforms and KPIs
- Feedback on TGA's Digital/Social media guidance (and the development of industry FAQs)
- Advice and support to members whose advertising was impacted by COVID-19 public health messages.

Consumer Medicine Information (CMI) reforms

CHP Australia's advocacy in relation to the CMI reforms delivered the following positive outcomes:

- CHP Australia's position included in all the reforms
- OTC specific outcomes regarding format and application
- OTC specific guidance
- Dedicated OTC template (with optional one-page summary)
- 5 year transition
- CHP Australia representation on EDWG
- Optional publication on the TGA website.

Scheduling and Scheduling Environment

CHP Australia continued its advocacy for greater consumer access to nonprescription medicines after successfully influencing policy outcomes in several areas during the MMDR. Some key highlights include:

- Appendix M reforms (including incentives for switch)
- Numerous positive decisions
- Successful defence of liquid paracetamol
- Labelling exemptions for modified release (MR) paracetamol
- Engagement with NZ decisions in relation to Paracetamol, Pholcodine and Dextromethorphan.

Country of Origin Labelling

We continued working cooperatively and productively with all stakeholders to articulate the issues and identify solutions to the country of origin labelling requirements for all medicines. Our aims are to ensure useful and pragmatic

reforms are put in place for complementary medicines and to ensure that other medicines are not adversely affected. Highlights include:

- Active participation in the consultations, reviews and on the taskforce
- New Country of Origin Labelling Regulations commenced in December 2019
- Changes to the Australian Consumer Law commenced in June 2020
- Input on the content of a foreshadowed Information Standard
- OTC medicines remain unaffected.

Low-risk products

In addition to the ongoing reforms as part of the MMDR roll-out, there were a number of reforms specific to low-risk products. Advocacy highlights include:

- Input into the TGA Pilot on antimicrobial lozenges
- Refinements to the listed medicines compliance rating scheme
- Changes to the regulatory classification of nappy rash products
- Fee-free period extended for permissible indications
- Refinements to the TGA proposals on sports supplements to avoid unintended impacts.

Labelling

The requirements of TGO92 continue to present issues for members. Some of the key actions included:

- Impact of TGO92 on product names clarified
- Vendor Qualification documents updated
- 2D barcode requirements clarified
- Allergen requirements clarified
- Contributed to the Parliamentary inquiry into allergies and anaphylaxis
- Transition arrangements for wholesalers and retailers clarified.

Others

We also provided advocacy and member assistance across a wide range of other regulatory areas, some of which included:

- Recalls and Crisis Management
 - Assistance with the industry response for NDMA contamination of ranitidine
 - URPTG updated incorporating our feedback

- 26BB (permissible Ingredients)
 - Improved process for new substances
 - Improved processes and transition arrangements for low-risk changes
 - Improvements to market exclusivity processes for new listed substances
- Policy agreement on data protection for listed (assessed) medicines
- Public access to ARTG information
 - TGA proposal modified to protect commercial information (e.g. flavours) and improve utility
- Generic medicines reforms (inadvertent OTC impacts avoided, possible future utility secured)
- Proprietary Ingredient issues examined (e.g. fragrances)
- General Safety Provision proposals
 - Meetings with other associations and members
 - Submission made
- Packaging covenant and therapeutic goods
- TGA changes to Regulatory Guidelines format
 - Feedback provided and incorporated
- PIC/S Guide For GMP PE009-14 review and guidance to support adoption from 1 July 2020.
- TGA's Digital Transformation (feedback to inform funding proposal provided)
- TGA's Evidence Guidelines (strategies being developed)
- Modern slavery (keeping up-to-date; assisting members as required)
- Cancellation of ARTG entries (issues explored)
- Section 14 reforms examined
- Crisis Management Guidelines (policy, content and application under review)
- Sunscreen ingredient pathway proposals (successful collaboration and modified outcome)
- AS/NZS 2604:2012 Sunscreen Standard review and drafting commenced to incorporate revised versions of ISO 24444, ISO 24443 and the new ISO 16217 Water Resistance – Water Immersion Procedure.

Developing a National Self-Care Policy

AUSTRALIAN SELF-CARE ALLIANCE



CHP Australia spearheaded the establishment of the Self-Care Alliance in 2014 at Parliament House, Canberra, bringing together stakeholders with an interest in advancing self-care. In 2019 CHP Australia along with other members of the Alliance, commissioned the Mitchell Institute at Victoria University to advance the development of a policy framework for self-care. The health policy expertise at Victoria University will help take self-care to a new level as it advocates for self-care to be acknowledged as a component of our national healthcare policy.

This year, building from their landmark report in 2018 entitled "The State of Self Care in Australia", the Mitchell Institute developed a national policy blueprint; this blueprint is an urgent call to action for government, individuals, health professionals and service providers to recognise the critical role of self-care in achieving and maintaining good health. The world-leading policy blueprint is endorsed by more than fifty experts and key self-care stakeholders across

the country, and calls for new and inclusive policy proposals to support self-care and better health for all Australians. It was developed in collaboration with a network of health, self-care and policy experts, including consumers, health professionals and leading academics. The launch of this policy blueprint will be pivotal in securing a place for self-care in national policy and we are excited about the planned launch in October 2020!

And in this year of COVID-19, the Mitchell Institute also wrote a report entitled "Self-Care and Health: By All, For All – Learning from COVID-19". This report distils the opportunities arising from COVID-19 and how enhancing self-care capabilities can protect from and prevent current and future health threats such as preventable chronic diseases.

HEALTH LITERACY



A critical foundation for responsible self-care is health literacy. An ABS (Australian Bureau of Statistics) 2006 study showed that only 40% of Australians had satisfactory health literacy levels.

In 2019/20, CHP Australia continued our partnership with Life Education Australia to promote self-care and boost health literacy among Australian parents and teachers. For over 40 years Life Education has empowered children to make safe and healthy choices. Parents and teachers play a pivotal role in modelling healthy behaviours to children. It is important to arm them with the skills and knowledge they need to raise the next generation of healthy young Australians.

Beyond providing content on the key pillars of self-care, CHP Australia and Life Education Australia collaborated on an education campaign regarding the safe use of hand sanitisers for young children, particularly important during this time of COVID-19.





Responding to the rapid evolution of the external environment impacting consumer healthcare, GSCF commissioned Deloitte to undertake a comprehensive strategic analysis of the future of self-care to inform GSCF's policy response and action plan in relation to the following:

- The key trends that will shape the self-care market over the next 5–10 years
- What the future environment needed to look like to enable growth of the self-care market
- The actions GSCF could take at the global level to shape and amplify the work performed by regional/local organisations.

This led to the adoption of a new strategic plan, "The Future of Self-Care" under which three main pillars were established:

- **Trust:** enhance trust across the self-care industry on the issues that matter most to the industry's stakeholders, including through ongoing improvement of transparency,
- **Healthcare system sustainability:** gain acceptance of self-care as a cornerstone of national health policies,
- **Health data:** engage in the public debate on the value of health data to improve health outcomes including through self-care and to ensure the appropriate level of regulation that will facilitate access and provide adequate consumer protection.

Under the *Trust* pillar UK-based Echo Research conducted a survey of policy makers, regulators and bodies representing consumers and healthcare professionals as well as industry partners. The aim of the survey was to establish a baseline of the levels of trust amongst these stakeholders and to identify gaps in trust and opportunities for building trust. The high level of regulation of the industry to ensure safety and efficacy was one of

the key strengths revealed by the survey. Another insight gained from the survey was that codes of ethics/practice are regarded as an essential and tangible way of demonstrating a commitment to ethical standards and transparency. This led to the adoption of the GSCF's Code of Ethics in July 2020.

Gaining recognition of the value of self-care and advocating for the adoption of self-care in national health policies are the main focus of the second pillar, *Healthcare system sustainability*. Work is underway to create a "self-care readiness index" that will measure self-care attitudes and behaviours across ten countries as a representative global sample. As an NGO in official relations with the WHO this work will be done in full collaboration with WHO to better understand what changes consumers and other stakeholders want. Based on the results of the study, there will be a revision of the WHO self-care definition, and ultimately it will be included in the building blocks for the WHO's Universal Health Care (UHC) initiative.

One of the aims of the *Health Data* pillar is to promote the industry's stance that health data is a cornerstone of self-care and that the full impact of self-care cannot be realised without access to health data. The other goal is to actively engage in the debate on the regulation and safe use of health data and to advocate in the global health data arena on the value and appropriate use of health data.

The work done by GSCF will help shape and amplify the work performed by regional and local organisations across the globe.

The CHP Australia Board

BOARD OF DIRECTORS



Robert Barnes
Aspen (Treasurer)
(ceased 7/08/2020)



Jonathan Biddle
Care Pharmaceuticals



Glenn Cochran
RB (ceased 24/09/2020)



Lindsay Forrest
Consultant (Chair)



Andrew Jenkin
iNova (Vice-Chair)



James Jones
Secretary (ceased
26/11/2019)



Phil Lynch
(from 27/07/2020)



Alan Oppenheim
Ego Pharmaceuticals



Anish Patel
GSK (from 26/11/2019)



Mark Sargent
Bayer Australia



Seona Wallace
HealthOne (ceased
15/07/2020)



Stephen Walker
Sanofi (from
26/11/2019)

CHP AUSTRALIA BOARD COMPOSITION

The CHP Australia Board composition, nomination, elections and executive roles are all governed by the CHP Australia Constitution.

The CHP Australia Board consists of up to ten Directors as follows:

- Up to six Directors elected from the Official Delegates of the CHP Australia Ordinary Members (Elected Directors)
- Up to four Directors appointed by the Board (Skills-based Directors).

The Elected Directors each hold office for two years and every year three of the Elected Directors retire from the Board. In advance of each annual retirement, CHP Australia calls for expressions of interest and holds elections for the three Director positions to be vacated. This ensures that there are opportunities for new Directors while maintaining continuity of expertise.

While each Elected Director must be the Official Delegate of an Ordinary Member, the Skills-based Directors can be drawn from a much wider set of candidates (including, for example, Honorary Life Members, Associate Members and non-members).

The CHP Australia Elected Directors as at 30 June 2020:

- **Robert Barnes**, Aspen Australia (Treasurer)
- **Jonathan Biddle**, Care Pharmaceuticals
- **Alan Oppenheim**, Ego Pharmaceuticals
- **Mark Sargent**, Bayer Australia
- **Anish Patel**, GlaxoSmithKline Consumer Healthcare
- **Stephen Walker**, Sanofi Consumer Healthcare.

The CHP Australia Skills-based Directors as at 30 June 2020:

- **Glenn Cochran**, RB
- **Lindsay Forrest**, Consultant (Chair)
- **Andrew Jenkin**, iNova Pharmaceuticals (Australia)
- **Seona Wallace**, HealthOne.

CHP Australia Members

Current at time of printing.

ORDINARY MEMBERS




ASSOCIATE MEMBERS



Subcommittees and Working Groups

CHP Australia has several subcommittees and working groups that meet regularly throughout the year to work on specific projects and issues that arise. This gives members the opportunity to:

- Contribute to the CHP Australia position on key issues
- Shape industry work
- Keep up to date with current issues
- Meet with the TGA.




If you are interested in learning more about our subcommittees please contact us: info@chpaustralia.com.au

CHP Australia – Your Support Team

CHP AUSTRALIA SECRETARIAT

Current at time of printing.



ADCHECK SERVICE

(previously the Advertising Services Managers for the TGA mandatory pre-approvals system)



WE'RE HERE TO HELP

General Enquiries:

Suite 1, Level 2
35 Chandos St,
St Leonards NSW 2065

Ph: +61 2 9922 5111
info@chpaustralia.com.au

AdCheck Enquiries:

Ph: +61 2 9922 5111
adcheck@chpaustralia.com.au

CHP Australia Events

Throughout the year, CHP Australia conducted numerous events. Attendance to our events was excellent, particularly as we transitioned to virtual workshops and webinars during COVID-19.

Highlight events include:

- 2.8.19 – Melbourne Therapeutic Goods Advertising Code (TGAC) Workshop
- 16.8.19 – Sydney Therapeutic Goods Advertising Code (TGAC) Workshop
- 7.11.19 – Diamond Awards
- 12.11.19 – Melbourne Therapeutic Goods Advertising Code (TGAC) Workshop
- 25.11.19 – CHP Australia Parliamentary Event
- 26.11.19 – CHP Australia AGM & Stakeholder Summit
- 28.11.19 – Building Trust in an Age of Rage
- 28.11.19 – Sydney Therapeutic Goods Advertising Code (TGAC) Workshop
- 5.3.20 – Melbourne Therapeutic Goods Advertising Code (TGAC) Workshop
- 16.4.20 – TGA: Your Advertising Obligations & Liabilities Webinar
- 28.4.20 – 2D DataMatrix codes: What serialisation means to the Supply Chain
- 1.5.20 – CHP Australia Member Forum: Industry & Political Landscape before and after COVID-19 Pandemic
- 4.6.20 – Health & Wellbeing Marketing Communications in the time of Coronavirus & beyond
- 25.6.20 – Polishing your Diamonds – Fundamentals for a Good Award Entry & Effective Marketing Plan



CHP AUSTRALIA MEMBER SERVICES



Advice and Support

- Pool of expertise to utilise
- Confidential advice on regulatory, technical, marketing and management issues
- Member workshops to navigate current/pending regulatory reforms



Advocacy and Representation

- “Voice of industry” on issues impacting industry, segments, ingredients
- Member conduit to media, stakeholders, government, TGA
- Strength in numbers



Shaping Industry Initiatives

- Committee, working group involvement
- Share experiences with other members
- Contribute to the CHP Australia position/shape industry work



Staying informed

- Keep up to date on issues
- Local and international monitoring of issues with briefs and alerts to members
- E-newsletters, alerts, events, seminars, workshops, web portal



Self Regulation

- CHP Australia Code
- CHP Australia Complaints Panel



Member Events

- World Class Industry Events
- Education Seminars
- Members Forums
- Parliamentary Events
- CHP Australia Diamond Awards for Excellence in Marketing & Sales



Member Training

- In house training and inductions
- Therapeutic Goods Advertising Training
- Member workshops





Consumer Healthcare
Products Australia

General Enquiries:

Suite 1, Level 2
35 Chandos St,
St Leonards NSW 2065

Ph: +61 2 9922 5111

Fax: +61 2 9959 3693

info@chpaustralia.com.au

www.chpaustralia.com.au

ABN 55 082 798 952

Membership Enquiries:

Membership Services Manager
CHP Australia

Ph: +61 2 9059 2439

AdCheck Enquiries:

Ph: +61 2 9922 5111

adcheck@chpaustralia.com.au

Media Enquiries:

Public Affairs Manager
CHP Australia

Ph: +61 2 9059 2442